Online citations, reference lists, and bibliographies.
← Back to Search

Phase II Study Of Gemcitabine Plus Docetaxel As Second-Line Treatment In Malignant Pleural Mesothelioma: A Single Institution Study

Ioannis S Tourkantonis, N. Makrilia, M. Ralli, C. Alamara, I. Nikolaidis, S. Tsimpoukis, A. Charpidou, A. Kotanidou, K. Syrigos
Published 2011 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Objective: The combinations of cisplatin-pemetrexed and cisplatin-gemcitabine are considered the standard systemic therapy for malignant pleural mesothelioma (MPM), which is a rapidly progressive tumor. The purpose of the present study is to evaluate the efficacy, safety, and clinical benefit of the gemcitabine plus docetaxel regimen in the second-line treatment of this disease. Patients and Methods: A total of 37 patients with MPM were treated with the combination of docetaxel (80 mg/m2) and gemcitabine (1000 mg/m2) on day 1 and 14 of a 28-day cycle. The regimen was repeated for a maximum of 6 cycles or until disease progression or unacceptable toxicity. Results: There was partial response of the disease in 7 patients (18.9%), whereas it remained stable in 23 patients (62.2%) and progressed in 7 patients (18.9%). The median time to disease progression was 7 months (range: 5.8–8.2 months) with a mean survival of 16.2 months (range: 13–19.3 months). Conclusion: The biweekly administration of docetaxel and gemcitabine, along with granulocyte colony-stimulating factor support, constitutes a safe, tolerable, and convenient regimen for the treatment of MPM, suggesting that this combination may be a viable option, especially in previously treated patients.
This paper references
Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial.
V. Georgoulias (2005)
A randomized multicenter phase III trial of topotecan monotherapy versus topotecan + etoposide versus topotecan + gemcitabine for second-line treatment of recurrent ovarian cancer.
J. Sehouli (2006)
Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.
P. Kosmidis (2008)
Gemcitabine and cisplatin: second-line chemotherapy for malignant mesothelioma?
N. Vogelzang (1999)
Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care?
V. Rusch (2003)
Gemcitabine and vinorelbine in pemetrexed‐pretreated patients with malignant pleural mesothelioma
P. Zucali (2008)
A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer
E. Karapanagiotou (2008)
Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.
C. Porta (2005)
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
A. Nowak (2002)
The European mesothelioma epidemic
J. Peto (1999)
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
Biweekly Administration of Docetaxel and Gemcitabine for Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Phase II Study
K. Syrigos (2007)
The role of gemcitabine in the treatment of malignant mesothelioma.
H. Kindler (2002)
Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study.
M. Ralli (2009)
European Organization for Research and Treatment of Cancer.
H. Fukuda (2000)
A phase I–II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens
C. Kosmas (2006)
Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985.
K. Antman (1988)
Gemcitabine versus Gemcitabine–Carboplatin for Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: A Prospective Randomized Phase II Study of the Hellenic Cooperative Oncology Group
P. Kosmidis (2007)
Interim results of a phase II trial of pemetrexed and oxaliplatin as 2nd/3rd line therapy in hormone refractory prostate cancer
T. Dorff (2008)
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
J. van Haarst (2002)
Phase II trial of ZD0473 as second-line therapy in mesothelioma.
G. Giaccone (2002)
Phase II trial of carboplatin in the treatment of patients with malignant pleural mesothelioma
EK Mbidde (1986)
Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program
P. Jänne (2006)
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma
A. Favaretto (2003)
Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.
K. Fizazi (2003)
External beam radiation therapy for the treatment of pleural mesothelioma.
E. Baldini (2004)
Bi-weekly administration of docetaxel and gemcitabine as first-line therapy for non-small cell lung cancer: a phase II study.
K. Syrigos (2005)
Biweekly administration of docetaxel and gemcitabine as adjuvant therapy for stage II and IIIA non-small cell lung cancer: a phase II study.
K. Syrigos (2007)
A phase II study of gemcitabine in patients with malignant pleural mesothelioma
J. van Meerbeeck (1999)
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study
V. Georgoulias (2004)
Second line chemotherapy in malignant pleural mesothelioma with oxaliplatin/gemcitabine abstract
M Serke (2006)
Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group.
C. Belani (2004)
Efficacy and safety of first‐ or second‐line irinotecan, cisplatin, and mitomycin in mesothelioma
D. Fennell (2007)
Pemetrexed as Second-Line Treatment in Malignant Pleural Mesothelioma after Platinum-Based First-Line Treatment
J. Sørensen (2007)
Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies.
D. Sugarbaker (2004)
Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial.
V. Georgoulias (2008)
Malignant pleural mesothelioma: a phase II trial with docetaxel.
D. Vorobiof (2002)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
J. Jassem (2008)
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.
C. Manegold (2005)

This paper is referenced by
Clinical efficacies of gemcitabine combined with docetaxel single or plus bevacizumab as second-line therapy for malignant pleural mesothelioma
C. Zhou (2018)
Second line therapy in malignant pleural mesothelioma: A systematic review.
W. Buikhuisen (2015)
Hypersensitivity Reactions to Docetaxel: Retrospective Evaluation and Development of a Desensitization Protocol
E. Syrigou (2011)
The role of interleukin-6 in malignant mesothelioma.
S. N. Abdul Rahim (2015)
Wczesne i odległe wyniki leczenia złośliwego międzybłoniaka opłucnej na podstawie analizy 170 przypadków
Bryl Maciej (2012)
Chemotherapy and radiotherapy for mesothelioma.
X. Dhalluin (2011)
Secondline chemotherapy versus best supportive care in patient with malignant pleural mesothelioma: a retrospective study.
H. Mutlu (2013)
Prise en charge diagnostique et thérapeutique du mésothéliome pleural malin
J. Delourme (2013)
Second-line treatment in malignant pleural mesothelioma: translating the evidence into clinical practice
G. Ceresoli (2014)
Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study
H. Mutlu (2014)
Mésothéliome pleural malin : la chimiothérapie est-elle la seule option thérapeutique ?
A. Scherpereel (2014)
Traitement du mésothéliome pleural malin en 2016
A. Scherpereel (2016)
Traitement de seconde ligne dans le mésothéliome pleural malin. Étude rétrospective française (2005–2006)
J. Margery (2010)
Characteristics and long‐term outcomes of advanced pleural mesothelioma in Latin America (MeSO‐CLICaP)
L. Rojas (2019)
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
A. Scherpereel (2020)
Emerging therapies for malignant pleural mesothelioma
J. Quispel-Janssen (2012)
Mesothelioma Interactome with 367 Novel Protein-Protein Interactions
Kalyani B. Karunakaran (2018)
A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma.
F. Petrelli (2018)
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.
I. Opitz (2020)
Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review
O. Abdel-Rahman (2015)
Role of Chemotherapy in the Management of Malignant Pleural Mesothelioma
L. Gianoncelli (2019)
Semantic Scholar Logo Some data provided by SemanticScholar